BAYER AG ISIN: DE000BAY0017 WKN: BAY001 Asset Class: Stock



Company Profile

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and womenšs health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	37,090,000,000		37,247,000,000		31,994,000,000	
Common stock capital		2,515,000,000		2,515,000,000		2,515,000,000
Fixed assets	86,254,000,000		93,637,000,000		94,784,000,000	
Equity capital of a company		33,078,000,000		38,926,000,000		33,168,000,000
Cash and cash equivalents	5,907,000,000		5,171,000,000		4,564,000,000	
Accrued liabilities		11,798,000,000		12,979,000,000		15,951,000,000
Other assets	-		-		-	
Current liabilities		29,457,000,000		35,084,000,000		29,403,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		60,809,000,000		56,874,000,000		64,207,000,000
Different income		-		-		-
Other liabilities		2,960,000,000		3,376,000,000		4,307,000,000
Total assets	123,344,000,000	123,344,000,000	130,884,000,000	130,884,000,000	126,778,000,000	126,778,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	99,723	101,369	99,637
Equity ratio	26.94%	29.86%	26.28%
Debt-equity ratio	271.19%	234.92%	280.53%

Others

	2023	2022	2021
Tax Expense Rate	-90.54%	10.46%	51.28%

BAYER AG

ISIN:	DE000BAY0017	WKN: BAY001	Asset Class: Stock
-------	--------------	--------------------	--------------------

Income statement			
	2023	2022	2021
Turnover	47,637,000,000	50,739,000,000	44,081,000,000
Net income	-2,941,000,000	4,150,000,000	1,000,000,000
EBIT	-100,000,000	6,267,000,000	3,119,000,000
Operating income before taxes	-1,459,000,000	4,820,000,000	1,997,000,000
Cash Flow	4,062,000,000	6,060,000,000	4,026,000,000
Net interest income	-1,359,000,000	-1,447,000,000	-1,122,000,000
Research and development expenses	5,371,000,000	6,572,000,000	5,412,000,000
Income taxes	1,321,000,000	504,000,000	1,024,000,000
Result from investments in subsidaries, associates and other	-162,000,000	-150,000,000	49,000,000
Revenues per employee	477,693	500,538	442,416

Board of Directors

Norbert Winkeljohann	Chairman of Supervisory Board
Barbara Gansewendt	Member of Supervisory Board
Ertharin Cousin	Member of Supervisory Board
Norbert W. Bischofberger	Member of Supervisory Board
Otmar Wiestler	Member of Supervisory Board
Paul Achleitner	Member of Supervisory Board
Simone Bagel-Trah	Member of Supervisory Board
Alberto Weisser	Member of Supervisory Board
Andrea Sacher	Member of Supervisory Board
André van Broich	Member of Supervisory Board
Claudia Schade	Member of Supervisory Board
Colleen Goggins	Member of Supervisory Board
Francesco Grioli	Member of Supervisory Board
Frank Löllgen	Member of Supervisory Board
Heike Hausfeld	Member of Supervisory Board
Heinz Georg Webers	Member of Supervisory Board
Horst Heinz Paul Baier	Member of Supervisory Board
Kimberly Marie Lein-Mathisen	Member of Supervisory Board
Michael Westmeier	Member of Supervisory Board
Yasmin Fahimi	Member of Supervisory Board

Members of Management Board

Chairman of Managing Board
Member of Executive Committee